Brain Repair UG

Healthcare

BrainRepair treatm. of massive brain damage & coma. With o. 70k affected newborns/year EU, there is no causal therapy for nonprogressive brain injuries in inf

Achievements

Team

Prototype

Users

Partners

Revenue

Investors

What we offer

Shareholding up to 20% - we are looking for seed capital of up to Eur 1.5 Million Euros.

Target group

300k patients per year - A number of patients with a form of non-progressive brain injury in Europe:
PVL Periventricular Leukomalacia - 3 in 100,000 - 15,000 in EU.
NE Neonatal Encephalopathy - 3 in 100,000 - 15,000 in EU.
PIH - Perinatal intracranial hemorrhage - 5.4 in 100,000 - 27,000 in EU.
CP Cerebral Palsy - 2 in 100,000 - 10,000 in EU.

Challenges

The shareholders of BrainRepair are seeking to raise EUR 55 Million in Equity. But right now we are looking for Seed Capital to get the project started. We need Euro 1.5 Million.

Our Story

One-of-a-kind: First and only curative treatment for infant non-progressive brain injury.
Safe: Autologous stem cells with no adverse effect, as demonstrated in multiple clinical trials, the risk profile equals that of any other (own) blood transfusion.
Effective: Clinical trial data show patients' motor function can be completely restored.
Simple process: No laboratory manipulation of blood is needed, stem cells can be infused by a treating physician without product-specific training or devices.
Market exclusivity: ODD for two indications, ensuring market exclusivity for 12 years.